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ABSTRACT
The major problems in human leukocyte antigen (HLA)-mismatched stem cell transplantation (SCT) are graft
failure and graft-versus-host disease (GVHD). Less-intensive regimens should be associated with a lower release of
inflammatory cytokines and possibly less GVHD. The objective of this study was to investigate whether HLA-
haploidentical SCT can be performed using nonmyeloablative conditioning and pharmacologic GVHDprophylaxis,
including glucocorticoids. Using conditioning consisting of fludarabine, busulfan, and anti–T-lymphocyte globulin
and GVHD prophylaxis consisting of tacrolimus and methylprednisolone (1 mg/kg/day), 26 patients who had
hematologicmalignancies in an advanced stage or with a poor prognosis underwent transplantation using peripheral
blood stem cells from an HLA-haploidentical donor (2–3 antigen mismatches in the graft-versus-host [GVH]
direction) without T-cell depletion. All patients except for 1 achieved donor-type engraftment. Rapid hematologic
engraftment was achieved (neutrophils > 0.5  109/L on day 12 and platelets > 20  109/L on day 12), with full
donor chimerism achieved by day 14. Fifteen patients did not develop acute GVHD clinically, and only 5 patients
developed grade II GVHD.The recovery of CD4T cells was delayed compared with that of CD8T cells. Sixteen
of the 26 patients are alive in complete remission. Four died of transplantation-related causes, and 6 died of
progressive disease. These data suggest that nonmyeloablative conditioning, GVHD prophylaxis consisting of
tacrolimus and methylprednisolone, and early therapeutic intervention for the GVH reaction allow stable engraft-
ment and effectively suppress GVHD in HLA 2–3 antigen-mismatched SCT.
© 2006 American Society for Blood and Marrow Transplantation
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bNTRODUCTION
Effective allogeneic stem cell transplantation (SCT)
egimens have been established using human leukocyte
ntigen (HLA)-matched donors. However,  70% of
atients who could beneﬁt from allogeneic SCT do not
ave a matched sibling donor. On the other hand, the
ikelihood of promptly identifying an HLA-haploidenti-
al donor within the family is  90%. In allogeneic
CT, 2 immunological barriers must be overcome:
1) the rejection barrier, or host-versus-graft (HVG)
eaction, and (2) the graft-versus-host (GVH) reac- cion. Because the occurrence of rejection or severe
cute GVH disease (GVHD) is reportedly associated
ith the degree of HLA incompatibility between the
onor and recipient [1,2], both of these barriers must
e more difﬁcult to overcome in HLA-haploidentical
ransplantation setting than in HLA-matched settings.
One useful approach to overcoming these barriers
s to use T-cell–depleted grafts. Since the 1990s, HLA
–3 antigen-mismatched (haploidentical) SCT has
een investigated by several groups, using partial T-
ell depletion combined with intensive immunosup-
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H. Ogawa et al.1074ression [3] or megadose CD34 cell transplantation
4,5]. These studies produced encouraging outcomes
egarding the achievement of engraftment or suppres-
ion of GVHD. Furthermore, Aversa et al. [6] recently
eported, in a phase II study treating 101 patients,
ood survival rates with excellent quality of life in
atients with transplantation in remission.
On the other hand, nonmyeloablative stem cell
ransplantation (NST) from an HLA-matched donor
as come to be generally accepted as a method of
llogeneic SCT for patients considered ineligible for
yeloablative preparative regimens because of ad-
anced age or comorbidities. The total body irradia-
ion (TBI) or high-dose cyclophosphamide (CPA)
ommonly used as conditioning treatments for con-
entional myeloablative SCT induces the production
f inﬂammatory cytokines, such as tumor necrosis
actor- and interferon-, known to be deeply in-
olved in the pathogenesis of GVHD [7]. Accord-
ngly, the use of nonmyeloablative conditioning may
ave an advantage in reducing the magnitude of the
VH reaction after HLA-haploidentical SCT. How-
ver, to date, there have been only a few reports on
tudies of NST from HLA-haploidentical donors
8–10]. To achieve bidirectional (GVH and HVG)
olerance, Sykes et al. used a nonmyeloablative con-
itioning consisting of high-dose CPA, thymic irradi-
tion, and anti–T-lymphocyte globulin (ATG) [8] or
nti-CD2 monoclonal antibody [9]. Furthermore,
’Donnell et al. [10] concluded that using high-dose
PA early after bone marrow transplantation attenu-
ted both the GVH and HVG reactions, and conse-
uently used a nonmyeloablative regimen including
udarabine, 2 Gy of TBI, and posttransplantation
PA. The 2 foregoing approaches were found to pro-
uce long-lasting mixed chimerism over the HLA
arrier (although further methodological improve-
ent is needed to suppress severe GVHD or graft
ejection).
We chose a conditioning regimen comprising ﬂu-
arabine, busulfan, and ATG to avoid the use of high-
ose CPA, which is associated with organ toxicities
eg, myocardial damage). This conditioning regimen
as originally established by Slavin et al. [11] for
LA-identical NST. We recently conducted a pilot
tudy of HLA-haploidentical NST using this condi-
ioning regimen [12] and found that stable, rapid do-
or engraftment was achieved; all of the patients
chieved almost 100% donor chimerism of both T-
ell and myeloid cell lineages by day 14. However,
yclosporine (CSP) or tacrolimus (FK506) mono-
herapy, the main GVH prophylaxis in that study, was
nsufﬁcient for controlling GVHD. In particular, dur-
ng the engraftment period, some patients developed
ery aggressive acute GVHD. These patients ﬁrst had
high fever for 2–3 days, with increased serum-solu-
le interleukin-2 receptor (sIL-2R) levels, followed Sy the development of GVHD symptoms, such as
kin eruption (unpublished data). Methylprednisolone
mPSL) 2 mg/kg was administered to control the
VHD symptoms with little effect; these patients
ltimately developed fatal thrombotic microangiopa-
hy (TMA) secondary to severe GVHD. Even intense
mmunosuppressive treatment has little effect once
VHD is fully established even in HLA-matched
CT [13]. Consequently, many investigators agree
hat GVHD should be prevented rather than treated.
Based on these ﬁndings, in the present NST pro-
ocol using HLA-haploidentical donors, we increased
he ATG dose and intensiﬁed the GVHD prophylaxis
using the combination of FK506  mPSL 1 mg/kg).
urthermore, we planned to perform early therapeutic
nterventions for signs or symptoms of GVH in the
ngraftment period (ie, high fever, increased sIL-2R
evel). We performed transplantation in 26 patients
ith hematologic malignancies in an advanced stage
r with a poor prognosis using peripheral blood stem
ells (PBSCs) from a related donor with HLA 2–3
ntigen mismatches (haploidentical) in the GVH di-
ection, and assessed the donor engraftment rate and
he incidence and severity of GVHD. We found that
his treatment regimen allowed stable engraftment
nd effectively suppressed GVHD after HLA-hap-
oidentical SCT.
ATIENTS AND METHODS
atients
The major objective of this study was to determine
he donor engraftment rate on day 35 after transplan-
ation, as well as the incidence and severity of acute
VHD. A total of 26 consecutive adult patients who
ad hematologic malignancies in an advanced stage or
ith a poor prognosis underwent SCT with a re-
uced-intensity preconditioning treatment using non–
-cell–depleted PBSCs from an HLA-haploidentical
elated donor (2–3 antigen mismatches in the GVH
irection) at Osaka University Hospital. The patient
roup comprised adult patients age 40 years or older,
long with younger patients considered ineligible for
yeloablative preparative regimens because of comor-
idities. The patients either lacked an available HLA-
dentical related or HLA-phenotypically identical un-
elated donor, or urgently needed a transplant. The
atient characteristics are given in Table 1. The clin-
cal courses of 3 of the 26 patients have been detailed
n previous reports [14–16]. More than half of the
atients were chemoresistant at the time of transplan-
ation. All 3 of the patients who underwent trans-
lantation in the ﬁrst complete remission (CR) had
hiladelphia chromosome–positive acute lymphoid
eukemia. Four patients had a previous autologous
CT, and all of them underwent HLA-haploidentical
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Nonmyeloablative HLA-Haploidentical Stem Cell Transplantation 1075ST due to recurrence of the original disease. Donors
nd patients shared 1 HLA haplotype, but the other
aplotype differed. The HLA disparities between do-
ors and recipients are shown in Table 2. Fourteen
nd 12 donors had 4/6 and 3/6 matches in the GVH
irection, respectively; 4, 13, and 9 donors had 5/6,
/6, and 3/6 matches in the HVG direction, respec-
ively. Seven transplantations were performed using
rafts from sibling donors; 4 patients received grafts
rom noninherited maternal antigen [17] (NIMA)-
ismatched donors, 2 received grafts from noninher-
ted paternal antigen (NIPA)-mismatched donors, and
he relevant status could not be examined for 1 donor–
ecipient pair. Nineteen transplantations were per-
ormed using grafts from offspring donors (11 sons
nd 8 daughters). The median patient age was 49.5
ears (range, 27–59 years).
Institutional review board approval was ob-
ained for the treatment protocol, and written in-
ormed consent was obtained from the patients and
able 1. Patient Characteristics
Patient UPN Disease Sex Age
Disease
status
1 218 CML M 50 CP2
2 227 AML M 53 CR2
3 109 MDS M 42 Overt
4 246 MDS M 29 Overt
5 266 AML M 41 CR2
6 269 NHL F 27 Re*
7 286 NHL M 45 Re*
8 288 AtCML M 53 CP
9 292 MDS M 54 Overt
10 297 AML M 52 CR2
11 299 NHL M 57 RR
12 302 AML F 44 CR2
13 304 ALL F 45 CR1(Ph)
14 306 MDS M 47 Overt
15 308 My/NK M 50 RR
16 310 ALL M 57 CR1(Ph)
17 315 ATL M 52 RR
18 316 NHL F 38 Re*
19 317 NHL F 49 RR
20 249 NHL M 54 Re*
21 322 MDS F 59 Overt
22 324 AML M 39 PR
23 328 AML F 46 RR
24 329 ALL F 51 CR1(Ph)
25 333 NHL F 47 RR
26 335 AML F 59 RR
ML, acute myeloid leukemia; ALL, acute lymphoid leukemia; CM
plastic syndrome; NHL, non-Hodgkin’s lymphoma; My/NK, m
complete remission; CR2, second complete remission; PR, part
second CP; overt, transformation from MDS to acute leukemia
ll of the patients with ALL who underwent allogeneic NST in
noninherited paternal antigen (NIPA)-mismatched sibling and
Sibling (U) indicates that whether the donor was an NIMA- or
The patient had a relapse after autologous peripheral stem cell traheir families. dreparative Regimen for Transplantation
Before conditioning, 13 patients who had progres-
ive disease at the time of transplantation received
hemotherapy for tumor reduction. Eight patients
ith myeloid leukemia received continuous intrave-
ous cytarabine 60 mg/m2/day for varying periods
6–14 days) depending on the tumor burden. Five
atients with B-cell lymphoma received rituximab 600
g twice.
The conditioning regimen comprised ﬂudarabine
0 mg/m2/day for 6 days (day 10 to day 5), oral
usulfan 4.0 mg/kg/day for 2 days (day6 to day5),
nd rabbit ATG (Fresenius, Munich, Germany) 2 mg/
g/day for 4 days (day 4 to day 1). To prevent the
naphylaxis caused by ATG, mPSL was administered
t 1 mg/kg on days4 to1 and thereafter continued
s GVHD prophylaxis at the same dose. PBSC mobi-
ization using granulocyte colony-stimulating factor
G-CSF) was performed as described previously [18].
wo leukapheresis procedures were performed on
or
Sex/age
(donor)
CD34 cells
( 106/kg)
CD3 cells
( 108/kg)
CD56 cells
( 107/kg)
(M) F/54 3.03 1.38 1.91
ter F/26 4.30 0.52 1.22
(P) M/38 7.50 3.59 8.10
(M) M/29 12.30 2.54 10.64
(P) M/34 7.40 2.22 3.13
(M) F/26 22.00 5.71 10.76
M/19 7.92 2.79 6.56
M/17 5.60 2.10 2.62
ter F/27 4.00 3.35 5.30
M/16 4.08 5.97 11.10
M/25 7.75 5.44 6.44
M/17 5.20 2.76 5.35
ter F/14 9.00 1.56 1.99
M/17 3.90 NT NT
M/22 6.20 1.71 3.31
ter F/28 11.00 2.50 3.40
M/24 6.90 1.33 3.27
ter F/14 5.10 2.48 6.15
M/20 4.30 1.99 2.61
(M) M/49 6.13 0.84 2.07
ter F/33 7.43 2.04 4.56
(U) F/37 9.80 3.68 4.25
M/20 2.45 2.73 4.05
M/23 8.50 3.07 3.36
ter F/19 5.20 3.24 5.69
ter F/31 8.78 3.21 6.41
onic myeloid leukemia; AtCML, atypical CML, MDS, myelodys-
natural killer cell leukemia; ATL, adult T-cell leukemia; CR1, ﬁrst
ission; Re, relapse; RR, resistant relapse; CP, chronic phase; CP2,
not tested.
had the Ph1 chromosome. Sibling (P) and sibling (M) indicate
erited maternal antigen (NIMA)-mismatched sibling, respectively.
-mismatched sibling was not determined.
tation.Don
Sibling
Daugh
Sibling
Sibling
Sibling
Sibling
Son
Son
Daugh
Son
Son
Son
Daugh
Son
Son
Daugh
Son
Daugh
Son
Sibling
Daugh
Sibling
Son
Son
Daugh
Daugh
L, chr
yeloid
ial rem
; NT,
CR1
noninh
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H. Ogawa et al.1076heresis, PBSCs were infused on days 0 (the day of
eukapheresis) and 1 without T-cell depletion. Pa-
ients received G-CSF if absolute neutrophil count
ANC) dropped to  0.5  109/L after transplanta-
ion.
VHD Prophylaxis and Treatment
FK506 treatment was initiated on the day before
ransplantation, given at 0.02 mg/kg/day in a contin-
ous infusion. Intravenous administration of mPSL
as started at a dose of 1 mg/kg/day from day 4 as
escribed earlier. The target blood concentration of
K506 was set at 10–15 ng/mL up to day 30, and
hereafter tapered in the absence of acute GVHD.
atients received intravenous FK506 therapy until
hey could reliably receive oral medications after
ransplantation. At that time, they were switched to an
ral dose calculated to be 4 times their current intra-
enous dose. The oral dose was administered in 4
ivided doses every 6 h. The dose reduction of mPSL
as started on day 15 and done relatively rapidly until
ay 30 (the target dose on day 30 was 0.5 mg/kg/day)
sing the serum sIL-2R level [19,20] as an indicator,
able 2. HLA Disparities Between Donors and Recipients
Patient UPN Recipient*
1 218 A26B61DR4/A24B52DR12
2 227 A24B51DR4/A11B46DR8
3 109 A24B35DR8/A24B15DR4
4 246 A24B7DR8/A31B54DR15
5 266 A11B62DR14/A24B61DR12
6 269 A24B61DR9/A24B48DR4
7 286 A24B46DR8/A31B61DR9
8 288 A2B55DR9/A24B52DR15
9 292 A24B52DR15/A24B35DR9
10 297 A24B52DR2/A2B62DR4
11 299 A24B48DR14/A2B51DR9
12 302 A24B54DR1/A11B70DR4
13 304 A31B51DR14/A11B35DR15
14 306 A11B51DR4/A24B39DR8
15 308 A24B7DR1/A31B54DR4
16 310 A24B52DR16/A26B35DR8
17 315 A11B62DR9/A24B52DR15
18 316 A24B62DR9/A2B60DR12
19 317 A24B62DR9/A2B39DR12
20 249 A2B60DR4/A24B61DR9
21 322 A2B46DR8/A24B7DR1
22 324 A11B67DR9/A2B62DR2
23 328 A2B71DR8/A24B52DR9
24 329 A26B39DR11/A24B61DR15
25 333 A2B35DR8/A26B51DR14
26 335 A26B39DR15/A2B62DR12
The HLA haplotype before or after a slash is one that is not or is s
underlined in recipients or in donors denote mismatched target
The locus(loci) of the mismatches are given in parentheses for cand carefully continued thereafter. At a dose of 0.5 sg/kg, mPSL was switched to an oral prednisone
ormulation (PSL).
Acute GVHD was graded according to standard
riteria [21]. Diagnosis and grading of chronic GVHD
ollowed the Seattle criteria [22]. The severity of dis-
ase was also assessed by the Karnofsky performance
ating. When GVHD ( grade I) was diagnosed, the
teroid dose was increased (mPSL 2 mg/kg/day at the
aximum dose) depending on the severity of GVHD,
nd mycophenolate mofetil (MMF) was started at a
ose of 15 mg/kg/day. When GVHD was resistant to
hese treatments, ATG was administered to patients
ith a CD3 cell count  500/L, and antitumor
ecrosis factor- antibody (inﬂiximab) 10 mg/kg was
dministered to the other patients. Patients who de-
eloped high-grade fever (above 38°C) while negative
or low-grade positive) for C-reactive protein during
he engraftment period, with obvious evidence for
acterial, fungal, or viral infections, were diagnosed as
aving GVH reaction and given inﬂiximab 10 mg/kg
ith the start of MMF 15 mg/kg/day. In patients who
eveloped TMA, the doses of FK506 and mPSL were
apered rapidly, and MMF 750–1000 mg/day was
Donor
No. of mismatched
antigens†
GVH HVG
26B60DR12/A24B52DR12 2(B, DR) 1(B)
24B52DR9/A11B46DR8 2(B, DR) 2(B, DR)
2B13DR12/A24B15DR4 2(B, DR) 3
2B13DR12/A31B54DR15 3 3
2B35DR8/A24B61DR12 3 3
2B54DR4/A24B48DR4 2(B, DR) 2(A, B)
2B61DR4/A31B61DR9 3 2(A, DR)
24B7DR1/A24B52DR15 3 2(B, DR)
11B61DR16/A24B35DR9 2(B, DR) 3
2B46DR9/A2B62DR4 3 2(B, DR)
26B61DR12/A2B51DR9 3 3
24B51DR11/A11B70DR4 2(B, DR) 2(B, DR)
2B46DR4/A11B35DR15 3 3
24B54DR4/A24B39DR8 2(A, B) 1(B)
24B60DR11/A31B54DR4 2(B, DR) 2(B, DR)
24B61DR9/A26B35DR8 2(B, DR) 2(B, DR)
2B52DR9/A24B52DR15 2(A, B) 1(A)
2B46DR8/A2B60DR12 3 2(B, DR)
2B62DR4/A2B39DR12 2(A, DR) 1(DR)
24B52DR15/A24B61DR9 3 2(B, DR)
2B35DR12/A24B7DR1 2(B, DR) 2(B, DR)
11B75DR4/A2B62DR2 2(B, DR) 2(B, DR)
2B61DR4/A24B52DR9 2(B, DR) 2(B, DR)
3B44DR13/A24B61DR15 3 3
33B61DR4/A26B51DR14 3 3
31B51DR8/A2B62DR12 3 3
etween donors and recipients, respectively. HLA antigens that are
ns in GVH or HVG reactions, respectively.
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K506 and steroid doses was sped up, depending on
he patient’s disease status.
The sIL-2R level was monitored to estimate the
egree of GVH response [19,20]. The normal sIL-2R
evel is  570 U/mL.
upportive Care
Each patient was isolated in a laminar air-ﬂow
oom, and standard decontamination procedures were
ollowed. Oral antibiotics (eg, ciproﬂoxacin, vancomy-
in, amphotericin B) were administered to sterilize the
owel. Patients with negative cytomegalovirus (CMV)
gG titers received blood products from CMV-sero-
egative donors. Intravenous immunoglobulin was ad-
inistered at a minimum dose of 100 mg/kg every 2
eeks until day 100. Cotrimoxazole was given for at
east 1 year for prophylaxis of Pneumocystis carinii in-
ections. Acyclovir was administered at 1000 mg/day
or 5 weeks after transplantation to prevent herpes
implex infections, then continued at 200 mg/day for
t least 2 years thereafter.
Ganciclovir 7.5 mg/kg/day in 3 divided doses was
dministered from day 10 to day 3 as prophylaxis
or CMV infection. Detection of CMV antigenemia
as performed using an immunoperoxidase-conju-
ated monoclonal antibody, HRP-C7, which binds an
mmediate–early antigen of CMV [23], pp65 antigen.
he degree of antigenemia was expressed as the num-
er of CMV antigen–positive cells per 50,000 leuko-
ytes. pp65 antigen testing in peripheral blood was
erformed once weekly. After grafting, ganciclovir
dministration was reinstituted in patients demon-
trating positive CMV antigenemia.
TMA was diagnosed according to Zeigler’s crite-
ia [24] and based on recent recommendations re-
orted by Nishida et al. [25].
himerism Analysis
After transplantation, serial blood samples were
nalyzed to determine the degree of donor/recipient
himerism in the T-cell– or neutrophil-enriched cell
raction, using polymerase chain reaction ampliﬁca-
ion of informative microsatellite regions to identify
ifferences between donor and recipient (based on
olymorphisms found in pretransplantation donor/
ecipient samples) [12]. To remove monocytes, KAC-
silica beads (Japan Immunoresearch Laboratories,
unma, Japan) were mixed with heparinized peripheral
lood and incubated at 37°C for 1 h. To enrich T cells,
negative selection system (RosetteSep; StemCell
echnologies, Vancouver, Canada) was used [26]. To
btain a T-cell–enriched cell fraction, a cocktail con-
aining anti-CD16, anti-CD19, anti-CD36, and anti-
D56 antibodies was added to the blood samples after
hey were treated with the silica beads. After Ficoll- daque (Pharmacia, Uppsala, Sweden) density-gradient
entrifugation, CD3 cells with a purity of  95%
ere recovered from the Ficoll–plasma interface.
eutrophils with a purity of  99% were recovered
rom the Ficoll–red blood cell interface.
tatistical Methods
Statistical analyses were performed with SPSS
oftware, version 11.0 (SPSS, Chicago, IL). Results
ere considered statistically signiﬁcant when P was 
05. Estimates of the incidence of acute GVHD and of
he probability of relapse were calculated using the
aplan-Meier method. Comparison of the incidence
f grade II acute GVHD between HLA 2 and 3
ntigen-mismatched NSTs was performed based on
he results of log-rank tests. In the analysis of event-
ree survival, rejection, relapse, death, and retrans-
lantation were deﬁned as events. Estimates of the
robability of event-free survival were calculated using
he Kaplan-Meier method.
ESULTS
ngraftment
Patients received PBSCs containing a median of
.55  106 (range, 2.45–22.0  106) CD34 cells/kg
ithout T-cell depletion. Consequently, a median of
.54  108 (range, 0.52–5.97  108) CD3 cells/kg
nd a median of 4.25  107 (range, 1.22–11.10  107)
D56 cells/kg were transfused. All but 1 patient
UPN 246) achieved donor-type hematopoietic en-
raftment (Table 3; Figure 1). In 6 patients (24.0%),
NC did not drop below 0.1  109/L, and for the
ntire group it took a median of 8 days for ANC to
rop below 0.1  109/L (Figure 1A). The median
uration of ANC  0.1  109/L was 2 days (range,
–13 days). Three patients (UPN 315, UPN 328, and
PN 329) never exhibited ANC  0.5  109/L. The
emaining 22 patients achieved neutrophil engraft-
ent (ANC  0.5  109/L) at a median of 12 days
range, 9–16 days) after transplantation (Figure 1B).
mong the 25 patients who achieved donor-type he-
atopoietic engraftment, 1 patient (UPN 306) had no
latelet recovery due to relapse. It took a median of 7
ays (range, 2–15 days) for the platelets to drop below
0  109/L (Figure 1C). The platelet count never
ropped below 20  109/L in 3 patients (UPN 315,
PN 328, and UPN 333), and these patients had no
eed for platelet transfusion. The remaining 22 pa-
ients achieved an unsupported platelet count of 20 
09/L at a median of 12 days (range, 9–28 days)
Figure 1D).
VHD
Fifteen (60.0%) of the 25 patients who achieved
onor-type engraftment did not develop acute GVHD
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H. Ogawa et al.1078linically (Table 3). Five patients (20.0%) developed
rade II acute GVHD (Figure 2). One of these
atients (UPN 315) developed cutaneous GVHD on
ay 39 after the rapid tapering of steroids and infusion
f donor lymphocytes (containing 1  106 CD3
ells/kg) for TMA and hemorrhagic cystitis. Another
atient (UPN 266) also developed grade II cutaneous
VHD on day 94 after the tapering off of steroids and
nfusion of donor lymphocytes for lymphoprolifera-
ive disease. All patients with grade II GVHD except
(UPN 308, who developed intestinal GVHD) ex-
ibited only skin lesions. In terms of the impact of an
LA disparity in the GVH direction on the occur-
ence of grade II GVHD, the incidence of acute
VHD was 14.3 % (2/14) for HLA 2 antigen-mis-
atched SCT and 27.3 % (3/11) for HLA 3 antigen-
ismatched SCT. There was no signiﬁcant difference
n the occurrence of acute GVHD between the 2
roups (P 	 .615; log-rank test). The treatment for
VHD was performed as described in Patients and
ethods. Two patients (UPN 297 and UPN 299) had
able 3. Outcome
Patient UPN Disease
Engraftment GVHD
Neu* Plt† acute chro
1 218 CML 12 12 0 NA
2 227 AML 13 16 0 Lim-S
3 109 MDS 13 27 0 NA
4 246 MDS   NA NA
5 266 AML 14 11 II‡ Ext-S
6 269 NHL 12 9 0 —
7 286 NHL 10 20 0 —
8 288 AtCML 14 28 0 Lim-S
9 292 MDS 11 14 I Ext-S
10 297 AML 15 16 0 Ext-S
11 299 NHL 10 10 0 —
12 302 AML 14 12 0 Lim-S
13 304 ALL 11 17 II Ext-S
14 306 MDS 16  I NE
15 308 My/NK 14 9 II —
16 310 ALL 9 9 I —
17 315 ATL   II‡ Ext-S
18 316 NHL 11 10 0 Lim-S
19 317 NHL 12 19 0 —
20 249 NHL 12 11 0 —
21 322 MDS 11 18 0 NA
22 324 AML 9 10 0 —
23 328 AML   I —
24 329 ALL  11 II —
25 333 NHL 14  I —
26 335 AML 11 14 0 NE
A, not applicable; NE, not evaluable; Rel, relapse; PD, progressiv
Lim, limited GVHD; Ext, extensive GVHD. GVHD organ inv
First day when ANC rose above 0.5  109/L.
First day when platelet count rose above 20  109/L; transfusion
The 2 patients (UPN266 and UPN315) developed acute GVHD
erative disease and severe hemorrhagic cystitis, respectively.
, Indicates that neutrophil and platelet count did not decrease to
, Indicates that neutrophil and platelet count did not recover tohigh-grade fever at the time of engraftment, which sas considered to indicate strong GVH reaction. Both
atients received inﬂiximab and MMF (see Patients
nd Methods), and neither patient developed acute
VHD clinically. In all of 5 patients with grade I
VHD and in 2 of 5 patients with grade II GVHD,
he GVHD was successfully controlled by increasing
he steroid dose and starting MMF. The remaining 3
atients with grade II GVHD also needed inﬂiximab
r ATG to suppress the GVHD. None of these 3
atients died of uncontrollable acute GVHD.
Of the 20 patients who could be evaluated for
hronic GVHD, 5 (25%) developed an extensive form
f chronic GVHD. All of these 5 patients had skin
esions, and 1 also had eye and mouth lesions. In these
ases, chronic GVHD was controlled by increasing
he doses of immunosuppressive agents. Although the
apering off of immunosuppressive agents or steroids
as done successfully in only 1 patient, those patients
ho survived for more than 1 year exhibited relatively
ood performance status (90%–100% Karnofsky per-
ormance score) under low doses of immunosuppres-
Survival
days
Performance
Status(%) Summary of outcome
62 — CR¡adenovirus infection
>1697 100 CR
39 — CR¡pulmonary fungal infection
>1438 100 rejection¡2nd NST¡CR
638 — CR¡Rel¡PD
>1159 100 CR
>907 100 CR
>857 100 CR
>810 100 CR
>720 100 CR
>696 100 CR
>664 100 CR
220 — CR¡Rel¡PD
165 — CR¡Rel¡PD
255 — CR¡Rel¡PD
>566 90 CR
382 — CR¡Rel¡PD
>471 100 CR
120 — PD
>355 100 CR
30 — CR¡TMA
140 — CR¡HC¡TMA
>209 100 CR
>195 100 CR
>118 100 CR
>69 100 CR
se; TMA, thrombotic microangiopathy; HC, hemorrhagic cystitis;
nt: E, eyes; O, oral; S, skin.
ndent.
e rapid tapering off of steroid and DLI because of lymphoprolif-
109/L and 20  109/L, respectively.
109/L and 20  109/L, respectively.nic
,E,O
e disea
olveme
-indepe
after th
0.5 ive agents (FK506 1–3 mg/day; PSL 5–15 mg/day).
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In all patients, chimerism status was monitored
hrough a quantitative polymerase chain reaction
ethod using informative microsatellite regions. In all
f the 25 patients who achieved donor-type hemato-
oietic engraftment, 95%–100% donor chimerism
as observed in T-cell and myeloid lineages by 2
igure 1. Engraftment of HLA-haploidentical stem cell allografts. C
A) and of patients who achieved ANC  0.5  109/L (B) is shown.
ere removed in (B). Cumulative percentage of patients in whom p
latelet counts recovered to  20  109/L (D) is shown. The data
ere removed in (D).Figure 2. Cumulative incidence of acute GVHD (grade II). aeeks after transplantation (data not shown). The
inetics of engraftment of donor hematopoietic cells
uring the ﬁrst 2 weeks after transplantation could be
nalyzed in 8 patients. As shown in Figure 3, donor
-cell engraftment was rapidly achieved; the median
tive percentage of patients who never achieved ANC 0.1 109/L
ta for 3 patients in whom ANC did not decrease to  0.5  109/L
counts never went below 20  109/L (C), and of patients in whom
atients in whom platelet counts did not decrease to  20  109/L
igure 3. Chimerism status during the early stage of transplanta-
ion. Open and closed bars indicate a median percentage of donor
D3 cells and neutrophils, respectively. Data from 8 patients wereumula
The da
latelet
for 3 pnalyzed.
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H. Ogawa et al.1080alue of donor T-cell components was 50.2% on day
, 93.9% on day 7, and 100% on day 11. Donor
eutrophil engraftment was slightly delayed compared
ith T-cell engraftment; the median value was 10%
n day 4, 0% on day 7, 84.4% on day 11, and 100% on
ay 14. In most patients, neutrophils were of host
rigin on day 7, and rapidly changed to donor origin
rom host origin between days 7 and 14.
ymphocyte Recovery and CMV Antigenemia
The CD4 T-cell count in the transplant cohort
n this study recovered slowly, with the median cell
ount exceeding 100  106/L at 9 months after trans-
lantation and 250 106/L at 18 months (Figure 4A).
n contrast, the CD8 T-cell count recovered more
apidly (Figure 4B).
CMV antigenemia occurred in 21 of 26 patients
80.8%). The median peak number of CMV antigen–
ositive leukocytes was 11.1 per 50,000 white blood
ells [WBCs] (range, 0.8/50,000–128.7/50,000). The
edian time to the maximum number of CMV anti-
en–positive leukocytes was day 35 (range, day 11–day
51). One patient (UPN 324) developed CMV en-
erocolitis, which was successfully controlled with fos-
igure 4. Lymphocyte recovery after HLA 2–3 antigen-mis-
atched NST. (A) CD4 cells. (B) CD8 cells. Horizontal barsdndicate median values.arnet. All CMV antigenemia was controlled by the
dministration of ganciclovir and/or foscarnet.
ther Complications
One patient (UPN 109) developed fatal fungal
neumonia during the neutropenic period (Table 4).
wo patients had bacterial infections (pneumonia and
holecystitis), which were successfully treated with
ppropriate antibiotics. Eleven patients (42.3%) de-
eloped hemorrhagic cystitis. In 8 cases, the causal
irus was detected: 3 cases of adenovirus, 4 cases of BK
irus, and 1 case of BK virus and JC virus . One patient
UPN 218) developed fatal adenovirus pneumonia af-
er hemorrhagic cystitis due to adenovirus. In other
atients, hemorrhagic cystitis was improved by con-
ervative therapy (hydration and/or bladder irrigation)
ith or without donor leukocyte infusion (DLI). Thir-
een patients (50.0%) developed liver dysfunction with
n increase to  3 times the normal upper transami-
ase limit. Most cases of liver dysfunction were due to
teroid- or drug-induced toxicities, and the transami-
ase level in these patients was normalized after the
ausative drugs were tapered or discontinued.
elapse, Causes of Death, and Survival
One patient (UPN 246) who experienced graft
ejection underwent retransplantation from the same
able 4. Adverse Events (%)
nfections
bacteria
bacteremia 0 (0)
others 2 (7.7)
fungus 1 (3.8)
virus
cytomegalovirus 1 (3.8)
others 2 (7.7)
Pneumocystis carinii 0 (0)
emorrhagic cystitis 11 (42.3)
ymphoproliferative disease 1 (3.8)
K506 encephalopathy 0 (0)
hrombotic microangiopathy 2 (7.7)
enoocclusive disease 0 (0)
iver dysfunction* 13 (50.0)
CI 1 (3.8)
aralytic ileus 2 (7.7)
ephrotoxicity† 0 (0)
yperglycemia‡ 12 (46.2)
ypertension 4 (15.4)
rrhythmia 1 (3.8)
enous thrombosis 2 (7.7)
septic necrosis 1 (3.8)
one fracture§ 1 (3.8)
CI, pneumatosis cystides intestinalis.
An increase to 3 times the normal upper limit of transaminase
level.
Nephrotoxicity requiring hemodialysis.
Insulin dose of 30 U/day was needed to control blood sugar.
Compression fracture of vertebral body.onor using a slightly intensiﬁed preconditioning treat-
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Nonmyeloablative HLA-Haploidentical Stem Cell Transplantation 1081ent, including 4 Gy of TBI [14]. As a result, this
atient achieved donor-type engraftment without de-
elopment of GVHD and remained in CR on day
438. Four patients had a transplantation-related
eath: 1 due to fungal infection, 1 due to adenovirus
nfection, 1 due to TMA after hemorrhagic cystitis,
nd 1 due to TMA. One patient (UPN 317) could not
chieve CR, and 5 patients experienced relapse at a
edian of 144 days (range, 22–324 days) after trans-
lantation. All of these patients died due to progres-
ive disease. The relapse rate at 3 years was 27.1% for
atients in CR/chronic phase (CP) (n 	 9) and 29.8%
or those in non-CR (n 	 17) at the time of trans-
lantation (Table 3). Fifteen patients survived in CR
t a median follow-up of 664 days (range, 69–1697
ays). The event-free survival at 3 years was 55.0%
64.8% for patients in CR/CP and 49.9% for those in
on-CR at time of transplantation).
ISCUSSION
One objective of the present study was to deter-
ine the donor engraftment rate using a non–T-cell–
epleted NST regimen from HLA-haploidentical
onors. The conditioning treatment comprising ﬂu-
arabine, busulfan, and ATG was sufﬁciently immu-
osuppressive to achieve the engraftment of HLA-
aploidentical donor grafts: 25 of the 26 recipients
96.2%) achieved donor-type engraftment. The use of
BSCs containing large numbers of T cells (median,
.54  108 CD3 cells/kg) and natural killer (NK)
ells (median, 4.25  107 CD56 cells/kg) should be
eneﬁcial. The duration and degree of pancytopenia
nd engraftment of the transplantation cohort in this
tudy were comparable to those found in HLA-
atched NST recipients by Slavin et al. [10]. The
edian duration of ANC  0.1  109/L was just 2
ays, resulting in a low incidence of severe infections
uring the neutropenic period (with only 1 patient
eveloping a fatal fungal infection). Seventeen of the
6 patients had 4/6 or 5/6 matches in the HVG di-
ection, which may have contributed to the rapid he-
atopoietic recovery.
The analysis of donor/recipient chimerism status
uring the ﬁrst 2 weeks after transplantation revealed
hat the very rapid engraftment of donor T cells, with
lmost 100% donor cell components on day 7. Of
ote, neutrophils were almost completely of host or-
gin on day 7 and rapidly converted from host to
onor origin over the following week (day 7–day 14)
Figure 3). These ﬁndings suggest that the achieve-
ent of full donor T-cell chimerism drove the elim-
nation of host hematopoietic cells, coupled with the
ncrease of donor hematopoietic cell components.
Another objective of the present study was to as-
ess the incidence and severity of acute GVHD. Less- bntensive regimens should be associated with lower
oxicity, less release of inﬂammatory cytokines, and
otentially less GVHD. However, Slavin et al. [11], in
study of NST from matched sibling donors using
onditioning with ﬂudarabine, busulfan and ATG, re-
orted severe GVHD ( grade II) in 38.5% of
ecipients. Other investigators reported that 28.3%
f HLA-matched NST recipients developed severe
VHD using a similar NST protocol [27]. In addi-
ion, in the present study, the risk of acute GVHD
hould have increased markedly due to the use of an
xtensively HLA-mismatched donor and the rapid
chievement of full donor chimerism after SCT.
owever, among the 25 patients who achieved donor
ype engraftment, only 5 (20%) developed severe
VHD (grade II). Considering that 2 of these patients
UPN 266 and UPN 315) developed GVHD after the
apid tapering off of steroids and DLI for lymphopro-
iferative disease or severe hemorrhagic cystitis, severe
VHD can be considered mostly suppressed.
The reasons behind the lower incidence of severe
VHD in the transplantation cohort in this study
emain to be determined. To intensify GVHD pro-
hylaxis, we chose a combination of FK506 and
PSL. Steroids are effective for most patients with
cute GVHD and thus also should be useful in the
rophylaxis of GVHD. However, their role in the
revention of GVHD is not well established in HLA-
dentical sibling BMT. The addition of steroids to
SPMTX signiﬁcantly reduced the incidence of
cute GVHD in the studies of Ruutu et al. [28] and
hao et al. [29], but not in those of Atkinson et al. [30]
nd Storb et al. [31].
In GVHD prophylaxis containing steroids, the
peed of steroid tapering may affect the incidence of
evere GVHD. For instance, in the study of Storb et
l. [31], in which no beneﬁcial effect of steroids on the
ccurrence of acute GVHD was observed, PSL was
nitiated on the day of transplantation at 1 mg/kg per
ay; the dose was halved at 3 weeks, and PSL was
iscontinued 35 days posttransplantation. In that
tudy, acute GVHD occurred mainly after day 22. In
ontrast, a study reported by Chao et al. [29], in which
teroids were tapered slowly over 180 days, found only
9% incidence of severe GVHD (II–IV) in patients
eceiving CSP  MTX  steroid prophylaxis. Fur-
hermore, our previous study of 20 consecutive cases
f unrelated bone marrow transplantation, including 3
ases of 2 allele-mismatched donors and 9 cases of 1
llele-mismatched donor, using GVHD prophylaxis
onsisting of FK506, MTX, and mPSL and a slowly
apered regimen of steroids, found complete suppres-
ion of acute GVHD grade II–IV [20]. These results
trongly suggest that the speed of steroid tapering is
mportant in transplantation involving steroid-con-
aining GVHD prophylaxis. In addition, steroids may
e more useful in HLA-mismatched allogeneic SCT
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H. Ogawa et al.1082han in HLA-matched allogeneic SCT. Even the
tudy of Storb et al. [31] found that in HLA-noniden-
ical BMT recipients, adding PSL signiﬁcantly de-
reased the incidence of acute GVHD (all 11 patients
ot given PSL and 6 of 12 patients given PSL devel-
ped acute GVHD; P 	 .01), although the reason for
his was not discussed. Furthermore, in our previous
tudy of HLA-haploidentical NST [12], in which pa-
ients received the same conditioning regimen as in
he present study (ie, combination of ﬂudarabine,
usulfan, and ATG, along with non–steroid-contain-
ng GVHD prophylaxis, such as CSP or FK506
onotherapy), 67% of the patients developed severe
cute GVHD. Based on these ﬁndings, we consider
hat adding steroids to GVHD prophylaxis contrib-
ted to the suppression of severe GVHD. Although
hao et al. [29] recommended steroid administration
rom day 7, we started the agent on day 0, because
onor T cells have been reported to proliferate much
ore rapidly and aggressively in major histocompati-
ility complex (MHC)-mismatched transplantation
ettings than in MHC-matched transplantation set-
ings [32].
Regarding the low incidence of severe GVHD,
nother point to emphasize is the importance of early
herapeutic intervention for GVH response. The typ-
cal pattern of GVHD during the engraftment period
s as follows. The patient presents with low-grade
ever under a negative test (or low-grade positive) for
-reactive protein at an early transplantation stage
day 5–7), when neutrophil counts are still decreasing.
he low-grade fever soon changes to a high-grade
piking fever. With the persistence of fever for ap-
roximately 3 days, skin eruptions becomes evident,
hich rapidly progress to generalized cutaneous le-
ions (erythroderma) with or without the development
f GVHD symptoms in other target organs (grades
I–IV). Starting mPSL 2 mg/kg immediately after the
ppearance of skin eruptions usually fails to suppress
he progression of GVHD. Even if GVHD symptoms
an be successfully controlled, life-threatening
VHD-associated complications, such as TMA, often
ccur later. Thus, we consider it important to initiate
he therapeutic intervention during the febrile period
efore GVHD becomes evident. In the present study,
he 2 patients treated in this manner avoided clinical
VHD. Once a patient manages to weather the storm
f the GVH reaction during the engraftment phase,
he magnitude of allogeneic response appears to be
apidly reduced thereafter, in part because massive
ctivation-induced cell death occurs in MHC-mis-
atched transplantation settings [33,34]. In the
resent protocol, because the neutropenic period was
ery short (as discussed in Results), fever due to bac-
erial or fungal infection occurred only rarely. How-
ver, the emergence of any sign or symptom suggest-ng infection warrants concurrent treatment for
nfection.
Rapid achievement of donor-type engraftment
fter transplantation must have an advantage in
erms of exerting antitumor effects by the allogeneic
mmunologic response [35]. All 4 patients with non-
odgkin’s lymphoma who had a relapse after re-
eiving autologous SCT achieved CR and have re-
ained in CR at a median follow-up of 689 days
range, 355–1159 days), strongly suggesting the
resence of a powerful graft versus leukemia (GVL)
ffect in this transplantation modality (although this
tudy involved only a small number of patients).
egarding the GVL effects exerted by HLA-hap-
oidentical grafts, several studies have shown that
K cell alloreactivity is associated with a signiﬁcant
VL effect, particularly in patients with acute my-
loid leukemia [36,37]. We could not assess the
VL effects by NK cells in the present study, be-
ause only 5 patients had a disparity in the killer
nhibitory receptor epitopes in the GVH direction.
n contrast, the recovery of CD4 T cells appeared
o be delayed after transplantation, possibly related
o long-term administration of immunosuppressive
gents (even at low doses). Although CMV antigen-
mia was observed in 21 of 26 patients (80.8%), the
ccurrence of CMV disease could be effectively
revented by early and appropriate administration
f ganciclovir or foscarnet. However, this delayed
ecovery of CD4 T cells may have led to several
ypes of viral infection. Three patients developed
ife-threatening viral infections: adenoviral pneu-
onia (UPN 218), human herpesvirus-6 encephali-
is (UPN 286), and lymphoproliferative disease
UPN 266). Consequently, viral infections should
e carefully monitored for in this transplantation
odality.
In conclusion, in non–T-cell–depleted HLA-hap-
oidentical (2–3 antigen-mismatched) SCT using non-
yeloablative conditioning comprising ﬂudarabine,
usulfan, and ATG, along with GVHD prophylaxis
ith FK506 and mPSL (1 mg/kg/day), donor-type
ngraftment was achieved in 25 of 26 patients
96.2%), and only 5 patients (20%) developed severe
cute GVHD. Thus, our ﬁndings demonstrate that
his transplantation procedure may be feasible for pa-
ients who are at high risk and lack available donors
nd also for those considered ineligible for myeloab-
ative preparative regimens due to advanced age or
omorbidities, although our results need to be con-
rmed in a large-scale study.
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